Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Smith & Nephew plc (SN.) Ordinary USD0.20

Sell:1,341.00p Buy:1,342.00p 0 Change: 9.50p (0.70%)
FTSE 100:0.08%
Market closed Prices as at close on 17 September 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:1,341.00p
Buy:1,342.00p
Change: 9.50p (0.70%)
Market closed Prices as at close on 17 September 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:1,341.00p
Buy:1,342.00p
Change: 9.50p (0.70%)
Market closed Prices as at close on 17 September 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.

Contact details

Address:
Building 5, Croxley Park, Hatters Lane
WATFORD
WD18 8YE
United Kingdom
Telephone:
+44 (020) 74017646
Website:
www.smith-nephew.com/

Important dates

Future events
Trading Announcement 04 November 2021 04/11/21
Interim dividend payment date 27 October 2021 27/10/21
Interim ex-dividend date 30 September 2021 30/09/21
Past events
Interim results 29 July 2021 29/07/21
Trading Announcement 29 July 2021 29/07/21
Quarter 2 results 29 July 2021 29/07/21
Final dividend payment date 12 May 2021 12/05/21
Trading Announcement 05 May 2021 05/05/21
Trading Announcement 29 April 2021 29/04/21
AGM 14 April 2021 14/04/21
Final ex-dividend date 01 April 2021 01/04/21
Annual report 01 March 2021 01/03/21
Quarter 4 results 18 February 2021 18/02/21
Final results 18 February 2021 18/02/21
Trading Announcement 11 January 2021 11/01/21
Trading Announcement 29 October 2020 29/10/20
Quarter 3 results 29 October 2020 29/10/20
Interim dividend payment date 28 October 2020 28/10/20
Interim ex-dividend date 01 October 2020 01/10/20

General stock information

EPIC:
SN.
ISIN:
GB0009223206
Market cap:
£11.79 billion
Shares in issue:
879.23 million
Sector:
Health Care Equipment & Services
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE 100,FTSE techMARK 100,FTSE 350,FTSE All Share,FTSE techMARK All Share

Key personnel

  • Roland Diggelmann
    Chief Executive Officer, Executive Director
  • Anne-Francoise Nesmes
    Chief Financial Officer, Executive Director
  • Brad Cannon
    President - Sports Medicine & ENT
  • Peter Coenen
    President - EMEA Region
  • Myra Eskes
    President - Asia Pacific
  • Simon Fraser
    President - Advanced Wound Management
  • Mark Gladwell
    President - Global Operations and Global Business Services
  • Skip Kiil
    President - Orthopedics
  • Vasant Padmanabhan
    President - Research & Development
  • Elga Lohler
    Chief Human Resource Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.